14:15:28 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2023
2023-11-13 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 Årsstämma 2023
2023-03-24 Extra Bolagsstämma 2022
2023-02-16 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2023-01-23 10:00:00

As of February 15, 2023, the Egoo CRP Capsule will be the first product in Qlife's Egoo portfolio to be introduced to the home market. The CRP test is soft-launched as a test without medical claims and will be followed by submission of the file for CE-mark, which allows for broader clinical applicability of the platform

With the launch of our CRP capsule, Qlife will start delivering on our vision of bringing lifestyle biomarker testing with quantitative precise data to a wider health conscious audience and for home use.

There is a growing demand and acceptance in the market for diagnostics self-testing. Now, health practitioners such as dieticians, nutritionists, physiotherapists and dentists can purchase the platform and assist in monitoring and interpretation of relevant biomarkers. Also, consumers will now be able to monitor and use the data in the context they wish, to optimize their athletic performance or to make necessary changes in lifestyle. Furthermore, Qlife will obtain CE-marks to broaden the clinical applicability of the platform.

"We are very excited to have reached this milestone. Our most important goal has always been to make Egoo Health available for non-professionals and for people in their home. The company is now taking this first step for general health empowerment to the people", says Thomas Warthoe, CEO of Qlife.

The Egoo Health, both device and CRP capsules, will be available for all customers to order on the Egoo Health webshop as of February 15. Capsules are available as single orders or as subscriptions. Based on Qlife's own information, this is the world's first self-test platform for immuno-diagnostics biomarkers.

Qlife was founded based on the idea that Egoo Health could help people lead a better life by using the diagnostics self-testing platform Egoo Health, Empowering a Better Being.